<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05086003</url>
  </required_header>
  <id_info>
    <org_study_id>0759-15</org_study_id>
    <nct_id>NCT05086003</nct_id>
  </id_info>
  <brief_title>Combined Kidney and Hematopoietic Stem Cell Transplantation for Tolerance Induction</brief_title>
  <official_title>Combined Kidney and Hematopoietic Stem Cell Transplantation for Tolerance Induction Between Matched Sibling Donor-recipient Pairs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combined transplantation of kidney and bone marrow between HLA-matched sibling&#xD;
      donor-recipient pairs to induce immune tolerance in order to enable complete discontinuation&#xD;
      of immunosuppressive therapy without kidney rejection. Hematopoietic stem cells are collected&#xD;
      from the donor 4 to 8 weeks before kidney transplantation, CD34 cells are enriched by&#xD;
      positive selection and cryopreserved. The day after kidney transplantation the recipient&#xD;
      starts conditioning therapy with thymoglobuline, total lymphoid irradiation, steroids,&#xD;
      tacrolimus and mycophenolate mofetil. Eleven days after kidney transplantation the stem cell&#xD;
      graft is thawed and infused to the recipient. If mixed donor chimerism is successfully&#xD;
      maintained more than 6 months without rejection, then immunosuppression may be tapered off&#xD;
      until complete discontinuation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Combined kidney and bone marrow transplantation</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of transplanted patients who were able to discontinue immunosuppression 12 months after transplantation.</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of transplanted patients who were able to discontinue immunosuppression 12 months after transplantation.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>Kidney and bone marrow transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined kidney and bone marrow transplantation after preparation with thymoglobuline and total lymphoid irradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Combined kidney and bone marrow transplantation</intervention_name>
    <description>Combined kidney and bone marrow transplantation</description>
    <arm_group_label>Kidney and bone marrow transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age older than 18 years&#xD;
&#xD;
          -  Matched siblings&#xD;
&#xD;
          -  No contra-indication to thymoglobuline or total lymphoid irradiation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women or breast feeding&#xD;
&#xD;
          -  Infection with HIV, HBV or HCV&#xD;
&#xD;
          -  Previous or presnt malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moshe Yeshurun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institution of Hematology, Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moshe Yeshurun, MD</last_name>
    <phone>0526015543</phone>
    <email>moshe.yeshurun@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liat Shargian, MD</last_name>
    <phone>0542394930</phone>
    <email>liatshr@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moshe Yeshurun</last_name>
      <phone>0526015543</phone>
      <email>moshe.yeshurun@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>moshe yeshurun</investigator_full_name>
    <investigator_title>Dr Moshe Yeshurun, Head Bone Marrow Unit</investigator_title>
  </responsible_party>
  <keyword>Renal transplantation</keyword>
  <keyword>Bone marrow transplantation</keyword>
  <keyword>Immune tolerance</keyword>
  <keyword>Immunosuppression</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

